Decreased expression of interleukin 13 in human lung emphysema

Boutten, A.; Bonay, M.; Laribe, S.; Leseche, G.; Castier, Y.; Leçon-Malas, V.; Fournier, M.; Durand, G.; Aubier, M.; Dehoux, M.; Crestani, B.
October 2004
Thorax;Oct2004, Vol. 59 Issue 10, p850
Academic Journal
Background: The overexpression of interferon (IFN)γ or interleukin (IL)-13 in the adult murine lung induces the development of changes that mirror human lung emphysema. Methods: IL-13 and IFNγ expression was determined in lung samples from five groups of patients: severe emphysema without α1-antitrypsin deficiency (SE+, n =10); severe emphysema with α1-antitrypsin deficiency (SE-, n = 5); mild localised emphysema (ME, n = 8); non-emphysema smokers (NE-S, n = 9), and non-emphysema non-smokers (NE-NS, n =11). Lung 11-13 and IFN7 mRNA were analysed by RI- PCR. Lung concentrations of IL- 13 protein were assessed by ELISA. Results: The expression of IFN7 mRNA was similar in patients with or without emphysema. IL-i 3 mRNA was markedly decreased in the SE+ group compared with the SE- (p =0.04), ME (p =0.02), and non- emphysema groups (p = 0.01). IL-i 3 mRNA correlated with forced expiratory volume in 1 second (r= 0.5, p = 0.04) and arterial oxygen tension (r= 0.45, p = 0.03) in emphysema patients. In contrast to the non- emphysematous lung, IL- 13 protein was below the detection limit of the assay in most emphysematous lung homogenates. Conclusion: The lung IL-i 3 content is reduced in patients with severe emphysema without α1-antitrypsin deficiency.


Related Articles

  • Comparative study of four different assays for the detection of binding antibodies against interferon-�. Gneiss, C.; Brugger, M.; Millonig, A.; Fogdell-Hahn, A.; Rudzki, D.; Hillert, J.; Berger, T.; Reindl, M.; Deisenhammer, F. // Multiple Sclerosis (13524585);Jul2008, Vol. 14 Issue 6, p830 

    Background Binding antibodies (BAB) against interferon-�(IFN�) are often determined as screening assays before performing an expensive and elaborate neutralizing antibody (NAB) test. Methods In this study, we compared four BAB tests, a western blot (WB), a direct binding enzymelinked...

  • Establecimiento y validación de un ensayo inmunoenzimático tipo ELISA, empleado en el control de calidad del Interferón alfa 2b humano recombinante. Valderrama, Susset; Pérez, Eliana; Aldama, Yurisleydis; Costa, Lourdes; Quintana, Marisel; Pérez, Gudelia; García, Gerardo // Revista VacciMonitor (Vacunología y Temas Afines);Jan-Abr2009, Vol. 18 Issue 1, p8 

    An ELISA for quantification of human recombinant alpha-2b Interferon in the Active Pharmaceutical Ingredient (API) was established and validated, and the validity criteria for the assay were defined, based on Good Laboratory Practices compliance. The following parameters were evaluated:...

  • Multivesicular liposome formulations for the sustained delivery of interferon a-2b. Jian Qiu; Xiao-hui Wei; Fang Geng; Rui Liu; Jing-wu Zhang; Yu-hong Xu // Acta Pharmacologica Sinica;Nov2005, Vol. 26 Issue 11, p1395 

    Aim: To develop and optimize a sustained release multivesicular liposome (MVL) formulation of interferon (IFN) a-2b. Methods: IFN a-2b MVL were prepared using a typical double-emulsion procedure. The sustained release effects of IFN a-2b MVL were investigated by monitoring the blood IFN a-2b...

  • Identification of Major Factors Influencing ELISpot-Based Monitoring of Cellular Responses to Antigens from Mycobacterium tuberculosis.  // PLoS ONE;2009, Vol. 4 Issue 11, p1 

    The article focuses on a study related to the use of interferon-c ELISpot protocols in studying antigen-specific immune responses. It identifies components of the different ELISpot protocols influenced assay sensitivity and inter-laboratory variation. The production of interferon-c (IFN-c) is...

  • An association between autoreactive antibodies and anti-interferon-β antibodies in multiple sclerosis. Garg, N.; Weinstock-Guttman, B.; Bhasi, K.; Locke, J.; Ramanathan, M. // Multiple Sclerosis (13524585);Aug2007, Vol. 13 Issue 7, p895 

    Approximately 5-25% of interferon-β (IFN-β) treated multiple sclerosis (MS) patients develop anti-IFN-β neutralizing antibodies (NAb) but the patient-specific variables associated with the risk of developing anti-IFN-β antibodies are poorly understood. Anti-IFN-β NAb are a subset...

  • Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons? Goletti, Delia; Raja, Alamelu; Kabeer, Basirudeen Syed Ahamed; Rodrigues, Camilla; Sodha, Archana; Carrara, Stefania; Vernet, Guy; Longuet, Christophe; Ippolito, Giuseppe; Thangaraj, Satheesh; Leportier, Marc; Girardi, Enrico; Lagrange, Philippe Henri // PLoS ONE;2010, Vol. 5 Issue 9, p1 

    Background: The suboptimal sensitivity of Interferon (IFN)-γ-based in-vitro assays, especially in immunocompromised individuals, emphasizes the need for alternative markers for diagnosing tuberculosis (TB). The objective of this study was to evaluate whether interferon-inducible protein...

  • Varicella-Zoster Virus-Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine. Weinberg, Adriana; Zhang, Jane H.; Oxman, Michael N.; Johnson, Gary R.; Hayward, Anthony R.; Caulfield, Michael J.; Irwin, Michael R.; Clair, James; Smith, Jeffrey G.; Stanley, Harold; Marchese, Rocio D.; Harbecke, Ruth; Williams, Heather M.; Chan, Ivan S. F.; Arbeit, Robert D.; Gershon, Anne A.; Schödel, Florian; Morrison, Vicki A.; Kauffman, Carol A.; Straus, Steve E. // Journal of Infectious Diseases;10/1/2009, Vol. 200 Issue 7, p1068 

    Background. The objectives of this study were to evaluate the association between varicella-zoster virus (VZV)— specific humoral and cell-mediated immunity (CMI) to herpes zoster (HZ) and protection against HZ morbidity and to compare immune responses to HZ and zoster vaccine. Methods. In...

  • Development of a Protein Biochip to Identify 6 Monoclonal Antibodies Against Subtypes of Recombinant Human Interferons. Zhenshan Xu; Weidong Du; Ping Zhang; Xuan Wang; Xueling Ma; Liqin Shi; Lihua Song // Assay & Drug Development Technologies;Apr2010, Vol. 8 Issue 2, p212 

    Recombinant human interferons (rhIFNs) are broadly used as effective therapeutic agents with antiviral, antitumor, and immune-modulating properties. Advances in protein biochip technology have benefited the medical community greatly, making true parallelism, miniaturization, and high throughput...

  • Age-related waning of in vitro Interferon-γ levels against r32kDaBCG in BCG vaccinated children. Anuradha, B.; Santosh, C. M.; Priya, V. Hari Sai; Latha, G. Suman; Murthy, K. J. R.; Lakshmi, Valluri Vijaya // Journal of Immune Based Therapies & Vaccines;2007, Vol. 5, p1 

    Background: Mycobacterium bovis BCG vaccine has displayed inconsistent efficacy in different trials conducted in various geographical regions. Nevertheless, it significantly reduces the risk of severe childhood tuberculosis and continues to be used to prevent tuberculosis in many countries. Many...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics